|
Drug Candidate Fails in Trial for Memory Improvement
Lexicon Pharmaceuticals’ LX6171 failed to improve memory in a Phase IIa trial testing the drug as a treatment for age-associated memory impairment.
Daily doses of the drug or placebo were given to 121 healthy elderly subjects with the condition for four weeks. Although the drug was well tolerated, it did not have significant effects on parameters of attention or memory, Lexicon said. The company said it may study the drug as a treatment for schizophrenia. |
Register Now
Archives